Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

MYSTERIOUS: Biogen stock analyst estimates ratings - You Need To See This

With a market cap of $20.4 billion, Biogen Inc. (BIIB) is a leading biopharmaceutical company specializing in treatments for neurological, rare, and immunological diseases. Headquartered in Cambridge, Massachusetts, Biogen has built its reputation as a pioneer in neuroscience, with decades of leadership in multiple sclerosis therapies, including Tecfidera, Avonex, and Tysabri. 

Shares of this leading biotechnology company have significantly underperformed the broader market over the past year. BIIB has declined 32.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 14.3%. In 2025, BIIB stock is down 9.1%, compared to the SPX’s 8.7% rise on a YTD basis. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.